Poxel: Funding, Investors & Team (Sep 2026)
Poxel is an innovative biopharmaceutical company that focuses on developing medications for metabolic diseases, particularly type 2 diabetes and non-alcoholic steatohepatitis (NASH). Established in Lyon, France in 2009 as a spin-off of Merck Serono, a prominent metabolic disorders company, Poxel is dedicated to addressing cellular energy regulation pathways as a means of treating metabolic diseases, as they believe that imbalances in these pathways are the root cause of these illnesses. Poxel's three main clinical stage pipeline programs target significant energy metabolism pathway targets. Imeglimin, their primary program, targets mitochondrial dysfunction, while PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), which acts as an essential energy regulator. Lastly, PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC).
Poxel has raised $9.9M across 2 funding rounds on record, the most recent an undisclosed round of $3.8M announced in Mar 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Poxel Company Profile and Key Stats
Latest funding round on record: Mar 2023.
Poxel Funding Rounds
Poxel raised $6.1M in a Post-IPO Equity announced in Aug 2022.
7 months later, an undisclosed round of $3.8M was announced in Mar 2023.
Poxel Founders and Leadership Team
No contact details are on record for this team yet.
Poxel Funding Compared to Other Biotechnology Startups
Poxel's latest round of $3.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Poxel in Biotechnology and Lyon
Companies Similar to Poxel
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Poxel Funding FAQs
What does Poxel do?
Poxel is an innovative biopharmaceutical company that focuses on developing medications for metabolic diseases, particularly type 2 diabetes and non-alcoholic steatohepatitis (NASH). Established in Lyon, France in 2009 as a spin-off of Merck Serono, a prominent metabolic disorders company, Poxel is dedicated to addressing cellular energy regulation pathways as a means of treating metabolic diseases, as they believe that imbalances in these pathways are the root cause of these illnesses. Poxel's three main clinical stage pipeline programs target significant energy metabolism pathway targets. Imeglimin, their primary program, targets mitochondrial dysfunction, while PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), which acts as an essential energy regulator. Lastly, PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC).
How much funding has Poxel raised?
Poxel has raised $9.9M across 2 rounds on record. The most recent is an undisclosed round of $3.8M announced in Mar 2023.
When did Poxel last raise funding?
Poxel's most recent funding round on record is an undisclosed round of $3.8M, announced in Mar 2023.
Who founded Poxel?
FundedIQ lists Sophie Bozec (Founder) at Poxel.
Where is Poxel headquartered?
Poxel is based in Lyon, Rhone-Alpes, France.
How many employees does Poxel have?
Poxel is in the 51-100 employee band.
How does Poxel's funding compare to other Biotechnology startups?
Poxel's latest round of $3.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Poxel Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Poxel is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.